Abbott launches first dual glucose-ketone monitor, sparking debate over wearables
Abbott received FDA clearance for the Libre Duo, a sensor that tracks both blood sugar and ketone levels, prompting mixed reactions from diabetics and clinicians.
Abbott's Libre Duo, now authorized by the FDA, adds continuous ketone measurement to its established glucose monitoring platform, offering a ten-day wearable that signals both sugar spikes and rising beta-hydroxybutyrate. Mark Taub of Abbott describes the feature as a "check engine light" for diabetic ketoacidosis, a fast-acting, potentially fatal condition. Clinicians such as David Ahn highlight its value for pediatric patients, insulin-pump wearers, and individuals taking SGLT2-inhibitor drugs, where traditional glucose alerts may miss danger.
Yet online communities report concerns about sensor precision, nuisance alerts, and the psychological toll of constant data. Abbott is limiting sales to prescription channels for now, though the company sees future opportunities in the broader metabolic-wearable market. The rollout underscores the promise and challenges of expanding health-tech data streams into everyday diabetes care.
Why it matters
Continuous ketone monitoring could give diabetics earlier warnings of life-threatening ketoacidosis, but accuracy and data fatigue remain concerns.
In this story
